Daewon Pharmaceutical Co., Ltd.

₩7,770As of Sun 8 Nov 2026, 12:00 UTC
KRX:003220Healthcare
Country South Korea
PE (Fwd) •••
TSR 10Y CAGR (4.02%)
Div yield 3.22%
ROE 0.83%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.04
PE TTM 70.69
TSR TTM (39.03%)
Mkt cap ₩166.5B
ROIC (0.01%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩9,057
16.56%
(25.60%)
Sell 4|5|1|7|12
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
178.96
178.71
191.02
190.81
31.75%
24.50%
28.15%
19.13%
Revenue₩B
23.31
23.86
24.71
26.06
13.94%
13.40%
12.36%
17.17%
Peers (US$122.8M)
Cap (US$)
PE
126.0M
3.284x
121.4M
—
Capital
TTM
5Y
10Y
Leveragex
3.345
(0.115)
(0.102)
EBIT/Intx
0.597
0.739
0.638
Own earn%
(64.67)
199.43
135.47
Sh yield%
27.05
31.57
31.97
Owners
Insiders/Inst%
14.79
66.52
Short interest%
0.59
SBC / revenue%
1.01
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
10–15
$1 testx
—
Incr. ROIC%
7